Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.215
-0.005 (-0.41%)
Sep 3, 2025, 2:29 PM - Market open

Lineage Cell Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2020
277111191199413264
Upgrade
Market Cap Growth
10.03%-41.93%-4.09%-51.84%56.44%98.01%
Upgrade
Enterprise Value
23679151134349228
Upgrade
Last Close Price
1.220.501.091.172.451.76
Upgrade
PS Ratio
24.6911.6621.3213.5395.13144.57
Upgrade
PB Ratio
5.761.443.082.774.542.78
Upgrade
P/TBV Ratio
45.955.2330.8412.4511.896.86
Upgrade
P/FCF Ratio
---307.85--
Upgrade
P/OCF Ratio
---187.79--
Upgrade
EV/Sales Ratio
21.648.3616.889.1180.50124.70
Upgrade
EV/FCF Ratio
---207.31--
Upgrade
Debt / Equity Ratio
0.050.030.050.050.030.04
Upgrade
Debt / FCF Ratio
---6.03--
Upgrade
Asset Turnover
0.110.090.080.100.030.02
Upgrade
Quick Ratio
3.963.472.023.072.325.35
Upgrade
Current Ratio
4.083.652.143.162.375.66
Upgrade
Return on Equity (ROE)
-71.51%-26.73%-32.07%-32.37%-46.52%-20.05%
Upgrade
Return on Assets (ROA)
-13.17%-12.53%-11.80%-9.44%-21.77%-14.16%
Upgrade
Return on Capital (ROIC)
-21.41%-18.58%-18.82%-16.61%-31.93%-15.35%
Upgrade
Earnings Yield
-14.81%-16.80%-11.27%-13.21%-10.42%-7.82%
Upgrade
FCF Yield
-8.38%-21.36%-15.33%0.33%-5.79%-7.51%
Upgrade
Buyback Yield / Dilution
-22.42%-15.94%-1.69%-3.22%-9.64%-3.10%
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q